• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Sanofi (Group) [since May 2011]

Sanofi-aventis is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, Sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). *

 

	Start	2011-05-06 renamed
	Predecessor	Sanofi-Aventis (Group)
	Industry	pharmaceutical
	Person	Hudson, Paul (Sanofi 201909– CEO before Novartis Head Pharma before AstraZeneca + Schering-Plough)
	Person 2	Contamine, Jérôme (Sanofi 2009–201809 CFO RETIRED 9/18)
	Region	Paris
	Country	France
	Street	174 avenue de France
	City	75635 Paris
	Tel	+33-1-5377-4000
		Address record changed: 2020-12-02
Basic data	Employees	I: 50,001 to 100,0 (2020-12-31)
	Currency	EUR
	Annual sales	36,041,000,000 (sales, net, consolidated (2020) 2020-12-31)
	Profit	12,350,000,000 (2020-12-31)
	Cash	13,915,000,000 (2020-12-31)
		* Document for �About Section�:
		Record changed: 2021-04-12

Advertisement

More documents for Sanofi (Group) [since May 2011]

• [1] Sanofi S.A.. (4/9/21). "Press Release: Sanofi Acquires Tidal Therapeutics, Adding Innovative mRNA-based Research Platform with Applications in Oncology, Immunology, and other Disease Areas". Paris & Cambridge, MA....
• [2] Enterome S.A.. (3/10/21). "Press Release: Enterome Strengthens Its Leadership Team with the Appointment of Anne Dagallier as Chief Business Officer"....
• [3] Hyloris Pharmaceuticals S.A.. (2/3/21). "Press Release: Hyloris Appoints Marieke Vermeersch as VP of Investor Relations and Corporate Communications". Liège....
• [4] Biond Biologics Ltd.. (1/12/21). "Press Release: Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor". Misgav....
• [5] Sanofi S.A.. (1/11/21). "Press Release: Sanofi to Acquire Kymab, Adding KY1005 to Its Pipeline, a Human Monoclonal Antibody Targeting Key Immune System Regulator OX40L". Paris & Cambridge....
• [6] Jeito Capital. (11/13/20). "Press Release: Sanofi Selects Jeito Capital as Its First Investment into a Private French-based Fund". Paris....
• [7] Kiadis Pharma N.V.. (11/2/20). "Press Release: Sanofi Offers to Acquire Kiadis for €308 Million". Paris & Amsterdam....
• [8] Sanofi S.A.. (8/17/20). "Press Release: Sanofi to Acquire Principia Biopharma". Paris & South San Francisco, CA....
• [9] GlaxoSmithKline plc. (7/31/20). "Press Release: Sanofi and GSK in Advanced Discussions with European Union to Supply up to 300 Million Doses of COVID-19 Vaccine". London & Paris....
• [10] GlaxoSmithKline plc. (7/31/20). "Press Release: Sanofi and GSK Selected for Operation Warp Speed to Supply United States Government with 100 Million Doses of COVID-19 vaccine". London & Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.